ABTL 0812

Drug Profile

ABTL 0812

Alternative Names: ABTL-0812; ABTL0812 (lipid analog therapeutic molecule); LP-10218

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lipopharma
  • Developer Ability Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Autophagy stimulants; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Non-small cell lung cancer
  • Phase I Solid tumours
  • Preclinical Neuroblastoma; Pancreatic cancer

Most Recent Events

  • 19 Feb 2018 The US FDA approves IND application for a phase I/II trial in Endometrial cancer and Non-small cell lung cancer
  • 31 Jan 2018 Ability Pharmaceuticals in collaboration with The Cleveland Clinic plans a phase I/II trial of ABTL 0812 in combination with gemcitabine and nab-paclitaxel for Pancreatic Cancer (Combination therapy, Metastatic disease, Late-stage disease, First line therapy) in September 2018 (NCT03417921)
  • 13 Dec 2017 The US FDA accepts IND application for ABTL 0812 in endometrial cancer and non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top